Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients

被引:115
作者
Burroughs, Thomas E.
Swindle, Jason
Takemoto, Steven
Lentine, Krista L.
Machnicki, Gerardo
Irish, William D.
Brennan, Daniel C.
Schnitzler, Mark A.
机构
[1] St Louis Univ, Ctr Outcomes Res, Dept Internal Med, St Louis, MO 63104 USA
[2] RTI hlth Solut, Res Triangle Inst, Res Triangle Pk, NC USA
[3] Washington Univ, Sch Med, Dept Med, St Louis, MO 63130 USA
关键词
post-transplantation diabetes; complications; immunosuppression;
D O I
10.1097/01.tp.0000259617.21741.95
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Data are scarce regarding the incidence and risk factors for complications of new-onset diabetes mellitus (NODM) in renal transplant patients. Methods. United States Renal Data System (USRDS) data from primary renal transplant recipients during 1995-2001 who developed NODM was used to examine diabetic complications over the first three years posttransplant. Prognostic models were used to evaluate patient characteristics and treatment choices associated with risk of each class of complications. Propensity scores for choice of calcineurin inhibitor were included in multivariate analyses. Results. The analysis included 21,489 patients, of whom 4,105 developed NODM by 3 years posttransplant. One or more NODM complications developed in 2,393 patients (58.3% of all patients with NODM), comprising ketoacidosis (334, 8.1%), hyperosmolarity (131, 3.2%), renal complications (1,286, 31.3%), ophthalmic complications (340, 8.3%), neurological complications (665, 16.2%), peripheral circulatory disorders (170, 41%) and hypoglycemia/shock (301, 7.3%). Complications developed within a mean of 500 to 600 days from diagnosis of NODM. Multivariate analysis showed that increased recipient age, higher body mass index, African-American race, hepatitis C infection, hypertension as cause of end-stage renal disease, cold ischemia >= 30 hours, and use of tacrolimus each increased risk of complications. Conclusion. NODM is associated with similar complications to those seen in the general population, but these appear to develop at an accelerated rate. Obesity and use of tacrolimus are the only modifiable factors that appear to affect risk of NODM or its complications.
引用
收藏
页码:1027 / 1034
页数:8
相关论文
共 39 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]  
Allison PD., 2010, SURVIVAL ANAL USING
[3]   Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus [J].
Bloom, RD ;
Rao, V ;
Weng, F ;
Grossman, RA ;
Cohen, D ;
Mange, KC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (05) :1374-1380
[4]  
D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO
[5]  
2-B
[6]   New-onset diabetes after transplantation: 2003 International Consensus Guidelines [J].
Davidson, J ;
Wilkinson, A ;
Dantal, J ;
Dotta, F ;
Haller, H ;
Hernández, D ;
Kasiske, BL ;
Kiberd, B ;
Krentz, A ;
Legendre, C ;
Marchetti, P ;
Markell, M ;
van der Woude, FJ ;
Wheeler, DC .
TRANSPLANTATION, 2003, 75 (10) :SS3-SS24
[7]   UK Prospective Diabetes Study 22 - Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM [J].
Davis, TME ;
Stratton, IM ;
Fox, CJ ;
Holman, RR ;
Turner, TC .
DIABETES CARE, 1997, 20 (09) :1435-1441
[8]  
Diabet Contr Complicat Trial Res Grp, 1998, ARCH OPHTHALMOL-CHIC, V116, P874
[9]   Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation [J].
Drachenberg, CB ;
Klassen, DK ;
Weir, MR ;
Wiland, A ;
Fink, JC ;
Bartlett, ST ;
Cangro, CB ;
Blahut, S ;
Papadimitriou, JC .
TRANSPLANTATION, 1999, 68 (03) :396-402
[10]  
EDIC Res Grp, 1999, DIABETES, V48, P383